

Open Call 2024 for Drug Discovery Projects

\*

Drug Discovery Projects

**SCOPE**

New identified targets often originate from academic research. Barriers to translation will be lowered by bringing best practices from industry into academic settings. Thus, this template provides guidelines for the assessment of a new collaboration for early-drug discovery projects and serves as a support for the creation of a robust preclinical data package.

**OUT OF SCOPE**

Fundamental research projects without a clear definition of activity aimed to generate an Asset to be transferred to the society as a solution to an identified unmet clinical need and/or projects presenting assets without possibility to generate new IP.

SUMMARY OF RULES

* Deadline for Applications: March 31st, 2024.
* Please send your application as one complete PDF to geral@accelbio.pt.
* You will receive an email acknowledging receipt of your application within five working days of submission. Should you have not received confirmation by then please contact the CoLAB AccelBio at geral@accelbio.pt.
* It is prohibited to remove sections or change the application form template. Incomplete applications will be rejected.
* For the Open Call guidelines, please refer to the Rules for Participation which can be found [here](https://accelbio.pt/careers/).

**SUMMARY**

**project title:**

**acronym:**

**select the therapeutic area that best suits your proposal (select one)**

\_\_\_ oncology

\_\_\_ neurosciences

\_\_\_ infectious diseases

\_\_\_ immunology

\_\_\_ metabolism

\_\_\_ cardiovascular

\_\_\_other (specify: )

**select the technology that best suits your proposal (select one)**

\_\_\_ therapeutic intervention

\_\_\_ diagnostic tools

\_\_\_ medical devices

\_\_\_advanced technologies

\_\_\_ other (specify: )

**project developmental stage (select one)**

\_\_\_ target validation (demonstrate that the target is directly involved in a disease process and that modulation of it is likely to have a therapeutic effect)

\_\_\_ hit identification (define new composition of matter by linking a chemical structure/biological to modulation of the target)

\_\_\_ lead optimization (drug-like molecule active in primary and secondary assays with acceptable specificity and selectivity for the target)

\_\_\_ admet (absorption, distribution, metabolism, excretion, and toxicity)

**project**

**brief description of your project/asset:**

» Describe your project/asset (500 characters, no spaces).

**scientific rationale:**

» Explain the scientific excellence and originality of the project/asset in the context of the state-of-the-art (1000 characters, no spaces). In addition, please indicate up to10 literature references related to the topic (These references will not count towards the character limit).

**supporting data:**

» Describe the preliminary data that supports the hypothesis and the scientific approach of your idea. The Figures and tables deemed necessary to support the understanding of the data should be added as an annex to this document. Please indicate what experimental models were used and if you have any human-based data (5000 characters, no spaces).

**need or problem to be solved:**

» Provide a description of the unmet clinical needs you anticipate the Asset/s may address. Please specify the potential primary indication. If applicable, please describe if the target is novel, or has it been previously therapeutically modulated? If applicable, include information on any existing tool compounds or approved drugs known to modulate the target (2500 characters, no spaces).

**goals and milestones to be achieved:**

» Outline and briefly describe the primary goals and milestones expected to be achieved within the 18-month project duration (2500 characters, no spaces).

» Please provide a Gantt chart for the project duration, including the milestones previously defined.

**ethics:**

» Describe possible ethical considerations related to the project. Justify the rationale behind the use of human samples and/or data, or animal models (1000 characters, no spaces).

For human samples/data:

» Do you plan to use human samples or/and data from an approved tissue bank, biobank, or any other repository in this research proposal?

Yes

No

» If you replied “Yes” to the last question, do you have an approved ethical project and signed informed consent forms from human subjects or patients for the use of their samples in this research proposal?

Yes

No

**mitigation plan:**

» Please indicate the critical risks for implementation of the project and proposed mitigation measures on.

Table 1: Risk-mitigation measures

|  |  |  |
| --- | --- | --- |
| Milestone | Description of the risk | Proposed risk-mitigation measures |
|  |  |  |
|  |  |  |
|  |  |  |
|  |  |  |
|  |  |  |
|  |  |  |
|  |  |  |
|  |  |  |
|  |  |  |

**TEAM**

**beneficiary institution:**

**project leader’s experience and expertise**

» Describe the capabilities of the project leader that would contribute to the development of the project. If applicable, list other affiliations other than your primary institution(1500 characters).

**complementarity of the team members**

» Provide details of the team member’s profile, previous experience, and dedication and commitment to the project. Describe how they are relevant and complementary for its successful execution (1500 characters, no spaces).

Table 2 - Team members (add extra lines for each team member)

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Full name | Job title | Institute | Email | Profile, experience | Dedication to the project |
|  |  |  |  | 1000 characters, no spaces | 1000 characters, no spaces |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
|  |  |  |  |  |  |

**is the project being developed by other institutions (co-pis)? if so, please specify**

» Please indicate if the project is being co-developed by other institutions. List the researchers involved and the role of each (500 characters, no spaces).

**IMPLEMENTATION**

**grants/funding**

» Please indicate if:

1. the development of the preliminary results was supported by a grant or contract (if yes, please specify):
2. there are any other current sponsored research agreements related to the project in place (if yes, please specify):

1. this project is the subject of a pending grant (if yes, please specify):

**financial resources**

» Please indicate if the primary lab has financial resources to support this project and to achieve the milestones proposed.

Table 3 – Project funding

|  |  |  |  |
| --- | --- | --- | --- |
| Milestones | Total Costs (€) | Funding secured (€) | Funding Sources |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |

**available infrastructure**

» Please provide information on the available infrastructure and tools available at the primary laboratory and/or research institute to support the project (1500 characters, no spaces).

**prior obligations**

» Please indicate if there are any agreements/obligations in place that are relevant to the project? Please specify (MTA, NDA, collaboration agreement, consortium agreement, other).

**publications**

» Please indicate if:

1. there is any prior disclosure related to the project:
2. the need to publish scientific results (including abstracts or public lectures) will put any patent application at risk (and prohibit successful out-licensing):

**intellectual property**

» Please indicate if there are any patents related to the project. If yes, please specify the protection status.

**BUSINESS CASE AND SOCIAL IMPACT**

**innovation:**

» Provide a description of how the proposal challenges and seek to shift the current research or clinical practice to address the unmet clinical needs you anticipate the Asset/s may address. Describe how the proposal aims to pursue novel targets, mechanisms and pathways, and what makes it distinct from other therapeutic approaches and its reasonable chance of success considering the landscape (2500 characters, no spaces).

**anticipated societal impact:**

» Explain how the project have the potential to enhance individuals' quality of life, foster social progress, and contribute to human development (2000 characters, no spaces).

**non confidential information:**

» Please provide a lay summary of your project without any confidential information to be promoted it broadly in the media. The text should be understandable by anyone (500 characters, no spaces).